Design of virotherapy for effective tumor treatment

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 4, 2010, Pages 403-411

  Garcia Aragoncillo, E ^a   Hernandez Alcoceba, R ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA DEFENSIN 2; BETA INTERFERON; CD137 LIGAND; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE URACYL PHOSPHORIBOSYLTRANSFERASE; CYTOTOXIC FACTOR; DELTAM51 PROTEIN; EPIDERMAL GROWTH FACTOR; FCU1 PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYALURONIDASE; INTERLEUKIN 12; INTERLEUKIN 24; JX 594; JX 963; M PROTEIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC PARAMYXOVIRUS; ONCOLYTIC POXVIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PRODRUG; RANTES; SODIUM IODIDE SYMPORTER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE INSERTION; GLIOMA; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; MEASLES VIRUS; MELANOMA; MESENCHYMAL STEM CELL; NEOPLASM; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; REVIEW; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS EXPRESSION; VIRUS REPLICATION; ANIMAL; GENE THERAPY; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TISSUE DISTRIBUTION; VIRUS REPLICATION;

EID: 77955343580     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Liu TC, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 4(2):101-117.
2. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW: Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog (2009) 5(5):e1000440.
3. Ylosmaki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, Saksela K: Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 82(22):11009-11015.
4. Lee CY, Rennie PS, Jia WW: MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res (2009) 15(16):5126-5235.
5. Kelly EJ, Nace R, Barber GN, Russell SJ: Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2010) 84(3):1550-1562.
6. Leja J, Nilsson B, Yu D, Gustafson E, Akerstrom G, Oberg K, Giandomenico V, Essand M: Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One (2010) 5(1):e8916.
7. Lee CY, Bu LX, Debenedetti A, Williams BJ, Rennie PS, Jia WW: Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther (2010) 18(5):929-935.
8. Gurlevik E, Woller N, Schache P, Malek NP, Wirth TC, Zender L, Manns MP, Kubicka S, Kuhnel F: p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication. Nucleic Acids Res (2009) 37(12):e84.
9. Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL: Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS One (2009) 4(4):e5119.
10. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 4(1):e4235.
11. Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, et al.: Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 69(8):3472-3481.
12. Guse K, Diaconu I, Rajecki M, Sloniecka M, Hakkarainen T, Ristimaki A, Kanerva A, Pesonen S, Hemminki A: Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther (2009) 16(8):1009-1020.
13. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R: Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther (2009) 17(4):614-622.
14. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG: Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 69(19):7713-7720.
15. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, et al.: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 4(4):263-275.
16. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, et al.: Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA (2010) 107(4):1576-1581.
17. Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J, Woo SL: Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2009) 16(3): 266-278.
18. Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, Garcia-Sastre A, Palese P, Fong Y: Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 17(4):697-706.
19. Altomonte J, Marozin S, Schmid RM, Ebert O: Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther (2010) 18(2):275-284.
20. Meng X, Nakamura T, Okazaki T, Inoue H, Takahashi A, Miyamoto S, Sakaguchi G, Eto M, Naito S, Takeda M, Yanagi Y, et al.: Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther (2010) 18(3):544-551.
21. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, Alemany R, Cascallo M: Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res (2008) 68(21):8928-8937.
22. Shashkova EV, May SM, Doronin K, Barry MA: Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther (2009) 17(12):2121-2130.
23. Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, Vassaux G, Marshall JF, Hart IR, Thomas GJ: In vivo retargeting of adenovirus type 5 to αvβ6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol (2009) 83(13):6416-6428.
24. Morrison J, Briggs SS, Green NK, Thoma C, Fisher KD, Kehoe S, Seymour LW: Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther (2009) 20(3):239-251.
25. Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G: Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA (2009) 106(22):9039-9044.
26. Jing Y, Tong C, Zhang J, Nakamura T, Iankov I, Russell SJ, Merchan JR: Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res (2009) 69(4):1459-1468.
27. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, et al.: Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res (2009) 15(13):4374-4381.
28. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA: Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 16(5):689-699.
29. Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, et al.: Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 16(12):1910-1918.
30. Aboody KS, Najbauer J, Danks MK: Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther (2008) 15(10):739-752.
31. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Δ24-RGD to human gliomas. Cancer Res (2009) 69(23):8932-8940.
32. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW: Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res (2009) 15(23):7246-7255.
33. Liu C, Russell SJ, Peng KW: Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 18(6):1155-1164.
34. Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S, Roth J, Lesniak MS: Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther (2009) 16(2):262-278.
35. Josiah DT, Zhu D, Dreher F, Olson J, McFadden G, Caldas H: Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther (2010) 18(2): 377-385.
36. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R: Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 17(10):1667-1676.
37. Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Del Mar Arriero M, Lassaletta A, Madero L, Ramirez M: Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: An exploratory study. Cancer Gene Ther (2010) 17(7):476-483.
38. Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, Qian W: Effective geneviral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation. Mol Cancer Ther (2009) 8(5):1387-1397.
39. Ziauddin MF, Guo ZS, OMalley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, et al.: TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther (2010) 17(4):550-559.
40. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY: Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene Ther (2009) 20(8):818-830.
41. Peerlinck I, Merron A, Baril P, Conchon S, Martin-Duque P, Hindorf C, Burnet J, Quintanilla M, Hingorani M, Iggo R, Lemoine NR, et al.: Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 15(21):6595-6601.
42. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E: Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 17(12):2041-2048.
43. Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, et al.: Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res (2010) 16(9):2540-2549.
44. Ahn M, Lee SJ, Li X, Jimenez JA, Zhang YP, Bae KH, Mohammadi Y, Kao C,Gardner TA: Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther (2009) 16(1):73-82.
45. Kojima Y, Honda K, Hamada H, Kobayashi N: Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J Surg Res (2009) 157(1):e63-e70.
46. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA (2009) 106(31):12915-12920.
47. Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimaki A, Pesonen S, et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2010) 84(2):856-866.
48. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R: Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther (2010) 18(7):1275-1283.
49. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release (2006) 114(2):230-241.
50. Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, Seidler DG, Kim JH, Yun CO: Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther (2010) 17(2):190-201.
51. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA: Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 15(8):2777-2788.
52. Schirmbeck R, Reimann J, Kochanek S, Kreppel F: The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther (2008) 16(9):1609-1616.
53. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG: Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 21(4):439-450.
54. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, et al.: A phase I trial of intravenous CG7870, a replicationselective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 14(1):107-117.
55. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, Monsurro V, et al.: Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics (2009) 10:301.
56. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA: Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 8(1):141-151.
57. Ramakrishna E, Woller N, Mundt B, Knocke S, Gurlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kuhnel F, Kubicka S: Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerasedependent oncolytic viruses. Cancer Res (2009) 69(4):1448-1458.
58. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, et al.: Phase II clinical trial of a granulocytemacrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 27(34):5763-5771.
59. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 17(3):718-730.
60. Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 9(1):64-71.
61. Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH: Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther (2010) 17(2):73-79.
62. Lei N, Shen FB, Chang JH, Wang L, Li H, Yang C, Li J, Yu DC: An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther (2009) 16(1):33-43.
63. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW: Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res (2009) 15(4):1317-1325.
64. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF: Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother (2009) 32(2): 145-156.
65. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF: Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 17(9):1626-1636.
66. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee M, Kim H, Yun CO: Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther (2010) 18(2):264-274.
67. Cafferata EG, Maccio DR, Lopez MV, Viale DL, Carbone C, Mazzolini G, Podhajcer OL: A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models. Clin Cancer Res (2009) 15(9):3037-3049.
68. Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, Jooss K: Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer Gene Ther (2009) 16(5):383-392.
69. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Hallden G: Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res (2009) 15(5):1730-1740.
70. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer (2009) 100(7):1154-1164.
71. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL: Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther (2009) 16(7):551-560.
72. Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB, Lesniak MS: Low-dose radiation enhances survivinmediated virotherapy against malignant glioma stem cells. Cancer Res (2008) 68(14):5778-5784.
73. Paiva LR, Binny C, Ferreira SC Jr, Martins ML: A multiscale mathematical model for oncolytic virotherapy. Cancer Res (2009) 69(3):1205-1211.
74. Reis CL, Pacheco JM, Ennis MK, Dingli D: In silico evolutionary dynamics of tumour virotherapy. Integr Biol (Camb) (2010) 2(1):41-45.
75. Mok W, Stylianopoulos T, Boucher Y, Jain RK: Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy. Clin Cancer Res (2009) 15(7):2352-2360.